ProMIS Neurosciences Announces Filing of Form 10 Registration Statement and Nasdaq Listing Application

TORONTO, Ontario and CAMBRIDGE, Massachusetts , June 22, 2022 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX:PMN.TO) (OTC-BB:ARFXF) (“ProMIS” or the “Company”), a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases, today announced that it has filed a registration statement on Form 10 (the "Registration Statement") with the United States Securities and Exchange Commission ("SEC") to register the Company's common shares (the "Common Shares") under Section 12(b) of the Securities Exchange Act of 1934, as amended, in connection with its application to list its Common Shares on the Nasdaq Capital Market (“Nasdaq”).